EXACT Sciences Co. (NASDAQ:EXAS) insider Kevin T. Conroy sold 101,488 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $45.72, for a total transaction of $4,640,031.36. Following the transaction, the insider now owns 931,540 shares in the company, valued at approximately $42,590,008.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
EXACT Sciences Co. (EXAS) traded up $0.04 on Tuesday, hitting $47.57. 1,876,123 shares of the company were exchanged, compared to its average volume of 3,387,089. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. EXACT Sciences Co. has a 12 month low of $18.50 and a 12 month high of $63.60. The firm has a market cap of $5,760.00, a price-to-earnings ratio of -41.37 and a beta of 0.58.
Institutional investors and hedge funds have recently bought and sold shares of the stock. C M Bidwell & Associates Ltd. acquired a new stake in shares of EXACT Sciences in the 4th quarter worth about $117,000. Crow Point Partners LLC bought a new stake in EXACT Sciences in the 4th quarter worth about $145,000. Oppenheimer Asset Management Inc. grew its position in EXACT Sciences by 2,925.7% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after purchasing an additional 3,072 shares in the last quarter. Advisory Services Network LLC grew its position in EXACT Sciences by 6,600.0% in the 4th quarter. Advisory Services Network LLC now owns 3,350 shares of the medical research company’s stock worth $176,000 after purchasing an additional 3,300 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in EXACT Sciences in the 3rd quarter worth about $183,000. Institutional investors own 83.12% of the company’s stock.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.